Ascendis Pharma (ASND) projected accelerating cash flow and a long-term product-revenue target of EUR 5 billion by 2030 during its presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday.
Shares were trading pre-market at $259.01, down 2.23% from Friday’s close of $264.92. The stock’s 52-week range stands at $186.05 to $282.15, and the company is valued at approximately $17.4 billion with a P/E ratio of 18.5.
Chief Executive Officer Jan Mikkelsen said the company will not raise capital. Management projected 2026 operating cash flow exceeding EUR 500 million and noted the figure could double or come in above that level in 2027. Future shareholder returns could reach up to EUR 1 billion annually.
Revenue growth is expected to approach 100% year-over-year, while expense growth is projected at only 10% to 15%, widening the margin between top-line gains and cost increases.
The company is executing a $400 million share repurchase program. On its balance-sheet profile, InvestingPro assigned Ascendis Pharma a financial-health score of 3.31 out of 5.
YORVIPATH, the company’s hypoparathyroidism treatment, has reached blockbuster status in 2026. It treats roughly 70,000 to 90,000 patients in the U.S., drawn from a broader global population outside America estimated at 400,000 to 500,000. Seven to eight countries beyond the U.S. are now fully commercial, and Ascendis recognizes revenue in more than 40 countries worldwide. The firm expects more than 1,000 new patients per quarter.
YUVIWEL, the achondroplasia therapy launched this year, is sold through a center-of-excellence model and has recorded 220 patient enrollments across more than 100 prescribers.
Combination-therapy data was a focal point. Mikkelsen said the first seven newborn patients on the dual treatment showed the expected safety profile and delivered results he called unprecedented.
"Never seen results like that," Mikkelsen said. "You basically generate three to four years of treatment in one year, plus additional effects we now see comparable to monotherapy — arm lengthening and other outcomes."
Two-year combination-therapy data is expected later this year, and five to ten trials are currently ongoing, many in late-stage development for label expansion and combination use. A once-weekly TransCon PTH candidate is being developed for stable patients already on YORVIPATH.
Looking ahead, Ascendis expects 10 to 15 additional countries to reach full commercial status in 2027, with further expansion in 2028. Two to three Phase III readouts are anticipated in 2027, and combined Phase I/II timelines for the cardiometabolic program are expected in early 2027.
Intellectual property protection and product durations extend through the 2030s and 2040s, providing a durable revenue base. A royalty agreement with BioMarin includes limited royalties in certain countries running through May 2030, at an effective rate expected in the single digits.
Investor sentiment remains elevated. The analyst consensus recommendation sits at 1.25, indicating a strong buy, with price targets ranging from $268 to $360. Mikkelsen emphasized the company’s strategy of independence despite prior collaboration failures.
"This is a major upside because I want to be independent," he said. "We have multiple collaborations. All of them have actually failed, but we have been extremely successful as a company."
The Vision 2030 target of EUR 5 billion in product revenue was described as a foundation target rather than peak sales potential.
